Miridesap | CAS#224624-80-0 | CPHPC | Ro-638695 | GSK-2315698

MedKoo Cat#: 327015 | Name: Miridesap

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Miridesap (also known as Ro-638695, GSK-2315698, and CPHPC) is an antineoplastic which depletes circulating serum amyloid P component (SAP) almost completely but leaves some SAP in amyloid deposits for specific recognition by subsequently administered therapeutic anti-SAP antibodies. Since Miridesap removes SAP from the blood, it also removes SAP from the cerebrospinal fluid (CSF).

Chemical Structure

Miridesap

CAS#224624-80-0

Theoretical Analysis

MedKoo Cat#: 327015

Name: Miridesap

CAS#: 224624-80-0

Chemical Formula: C16H24N2O6

Exact Mass: 340.1634

Molecular Weight: 340.38

Elemental Analysis: C, 56.46; H, 7.11; N, 8.23; O, 28.20

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 350.00	2 weeks
250mg	USD 650.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Miridesap； Ro-638695； Ro 638695； Ro638695；GSK-2315698； GSK 2315698； GSK2315698；CPHPC；CPOHPC （acid form; CPOHPC acid

IUPAC/Chemical Name

(2'R)-adipoyldi-D-proline

InChi Key

InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1

InChi Code

InChI=1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1

SMILES Code

O=C(N1[C@H](CCC1)C(O)=O)CCCCC(N2[C@H](CCC2)C(O)=O)=O

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.

In vitro activity:

In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid, that is a competitive inhibitor of SAP binding to amyloid fibrils. This palindromic compound also crosslinks and dimerizes SAP molecules, leading to their very rapid clearance by the liver, and thus produces a marked depletion of circulating human SAP. Reference: Nature. 2002 May 16;417(6886):254-9. https://pubmed.ncbi.nlm.nih.gov/12015594/

In vivo activity:

Addition of miridesap in the drinking water begun on day-10 had a significant effect upon survival of the mice. Miridesap-treated mice did not appear as sick as control mice following the intravenous injection of C. albicans, and they survived significantly longer than mice that received yeast cells only (p < 0.020). As can be seen, mice receiving miridesap survived the longest. Reference: Pathogens. 2022 Nov 6;11(11):1304. https://pubmed.ncbi.nlm.nih.gov/36365055/

	Solvent	mg/mL	mM
Solubility
	Ethanol	30.0	88.14
	PBS (pH 7.2)	10.0	29.38

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 340.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 2002 May 16;417(6886):254-9. doi: 10.1038/417254a. PMID: 12015594. 2. Klotz SA, Lipke PN. The Paradoxical Effects of Serum Amyloid-P Component on Disseminated Candidiasis. Pathogens. 2022 Nov 6;11(11):1304. doi: 10.3390/pathogens11111304. PMID: 36365055; PMCID: PMC9697064.

In vitro protocol:

In vivo protocol:

1. Klotz SA, Lipke PN. The Paradoxical Effects of Serum Amyloid-P Component on Disseminated Candidiasis. Pathogens. 2022 Nov 6;11(11):1304. doi: 10.3390/pathogens11111304. PMID: 36365055; PMCID: PMC9697064.

1: Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo. Open Biol. 2016 Feb;6(2):150202. doi: 10.1098/rsob.150202. PubMed PMID: 26842068; PubMed Central PMCID: PMC4772805. 2: Sahota T, Berges A, Barton S, Cookson L, Zamuner S, Richards D. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 Feb;4(2):e15. doi: 10.1002/psp4.15. Epub 2015 Feb 4. PubMed PMID: 26225229; PubMed Central PMCID: PMC4360666. 3: Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med. 2015 Sep 17;373(12):1106-14. doi: 10.1056/NEJMoa1504942. Epub 2015 Jul 15. PubMed PMID: 26176329. 4: Lu GW, Shao G. Hypoxic preconditioning: effect, mechanism and clinical implication (Part 1). Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014 Nov;30(6):489-501. PubMed PMID: 26016357. 5: Kolstoe SE, Jenvey MC, Purvis A, Light ME, Thompson D, Hughes P, Pepys MB, Wood SP. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC). Acta Crystallogr D Biol Crystallogr. 2014 Aug;70(Pt 8):2232-40. doi: 10.1107/S1399004714013455. Epub 2014 Jul 25. PubMed PMID: 25084341; PubMed Central PMCID: PMC4118831. 6: Millar DJ, Hutchinson WL, Pepys MB. Immunoradiometric assay for human serum amyloid P component. J Immunol Methods. 2011 Aug 31;371(1-2):18-24. doi: 10.1016/j.jim.2011.06.010. Epub 2011 Jun 25. PubMed PMID: 21708157. 7: Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010 Nov 4;468(7320):93-7. doi: 10.1038/nature09494. Epub 2010 Oct 20. PubMed PMID: 20962779; PubMed Central PMCID: PMC2975378. 8: Kolstoe SE, Wood SP. Drug targets for amyloidosis. Biochem Soc Trans. 2010 Apr;38(2):466-70. doi: 10.1042/BST0380466. Review. PubMed PMID: 20298204. 9: Gillmore JD, Tennent GA, Hutchinson WL, Gallimore JR, Lachmann HJ, Goodman HJ, Offer M, Millar DJ, Petrie A, Hawkins PN, Pepys MB. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol. 2010 Mar;148(5):760-7. doi: 10.1111/j.1365-2141.2009.08036.x. Epub 2010 Jan 8. PubMed PMID: 20064157. 10: Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619-23. doi: 10.1073/pnas.0902640106. Epub 2009 Apr 16. PubMed PMID: 19372378; PubMed Central PMCID: PMC2669789.